Please assess the completion status of the following clinical trial:

Trial Title: Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects \>65 years of age at the time of signing the informed consent form~2. A confirmed diagnosis of AML according to the 2008 WHO classification~   * This includes: Bone marrow aspirate with a good clot or biopsy for morphology, flow cytometry, cytogenetic analysis, and in case of normal cytogenetics, molecular genetic analyses including FLT3-ITD, NPM-1 and CEBP A~  * Bio-banking of leukemic cells at diagnosis performed (according to guidelines of the Swedish National AML biobank).~3. A documented CR or CRp achieved after one or two induction courses.~Exclusion Criteria:~1. Subjects who are not considered to be candidates to complete the consolidation therapy due to medical or psychological reasons.~2. Subjects who have taken any investigational drugs or participated in an interventional clinical trial within 30 days prior to screening.~3. Patients with acute promyelocytic leukemia~4. Patients with t(8;21) or inv(16)~5. CNS leukemia~6. Patients with a previous diagnosis of MDS, i.e. AML preceded by a diagnosed MDS~7. Subjects who are candidates for allogeneic stem cell transplantation (SCT)~8. Another cancer diagnosis with a life expectancy of less than two years

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azacitidine (Type: EXPERIMENTAL): Azacitidine 75mg/m2/d subcutaneously once daily for 5 days given every 5:th week for 8 cycles.
- DA (Type: ACTIVE_COMPARATOR): Two courses of DA in accordance with the Swedish National treatment program (reduced doses):~In case one induction course was given:~First consolidation course: daunorubicin 45 mg/m2 x 1 (iv infusion) day 1-3 and cytarabine 1000 mg/m2 x 2 (iv infusion) day 1-4.~Second consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~In case two induction courses were given:~First consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~Second consolidation course: cytarabine 200mg x 2 (fixed dose sc injection) day 1-5.

Based on this trial design, predict the completion outcome and termination type (if applicable).